TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22048576

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Formocresol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (freshly extracted carious teeth)
Number of subjects: 100
Study: 19101798

Group type: EXPERIMENTAL
Intervention: Endoscopic argon plasma coagulation (APC)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 57
Study: 16461077

Group type: EXPERIMENTAL
Intervention: Trospium chloride 20 mg twice daily
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study: 15290743

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg followed by 200 mg bid
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg bid
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 11387349

Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoladex and Tamoxifen in combination (ZT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 0
Study: 9232736

Group type: EXPERIMENTAL
Intervention: Extra Corporeal Shock Wave Lithotripsy (ESWL) and ureteroscopy (experimental group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not given information, not allowed to choose)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients who perceived they received information (both groups)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients who perceived they did not participate in decision-making (both groups)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients with lower educational level who perceived they received information
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Higher educated patients who perceived they participated in decision-making
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients with a passive coping style who perceived they received information or participated in decision-making
Number of subjects: 96
Study: 8448748

Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg, four times daily for 3 months)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 9
Study: 3761977

Group type: EXPERIMENTAL
Intervention: Cyclosporin A eyedrops
Number of subjects: 12
Study: 31721185

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 2886

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 2886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2886

Group type: COMPARATOR
Intervention: Galcanezumab and Placebo
Number of subjects: 2886
Study: 29246361

Group type: EXPERIMENTAL
Intervention: Preterm and SGA births
Number of subjects: 31988

Group type: EXPERIMENTAL
Intervention: Preterm-AGA births
Number of subjects: 31988

Group type: EXPERIMENTAL
Intervention: Term-SGA births
Number of subjects: 31988

Group type: EXPERIMENTAL
Intervention: LBW births
Number of subjects: 31988

Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 31988
Study: 27089519

Group type: EXPERIMENTAL
Intervention: Pradefovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adefovir dipivoxil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 0
Study: 24636474

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard of care (abstaining from peanut)
Number of subjects: 23
Study: 22727499

Group type: EXPERIMENTAL
Intervention: Acupuncture and etoricoxib
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture and etoricoxib
Number of subjects: 120

Group type: COMPARATOR
Intervention: Etoricoxib alone
Number of subjects: 120
Study: 20093149

Group type: EXPERIMENTAL
Intervention: GAD with comorbid MDD
Number of subjects: 39

Group type: COMPARATOR
Intervention: GAD without comorbid MDD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (GAD with and without MDD)
Number of subjects: 39
Study: 18256708

Group type: EXPERIMENTAL
Intervention: Single-item physical activity screening question
Number of subjects: 1171
Study: 15755321

Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners
Number of subjects: 78
Study: 11834991

Group type: EXPERIMENTAL
Intervention: PerCutaneous Compression Plate (PCCP)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 115
Study: 10408635

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12 mg Zn++/day for one month)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: HAART therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Zinc deficiency
Number of subjects: 67
Study: 8772215

Group type: EXPERIMENTAL
Intervention: Fragmin (low-molecular-weight heparin) administered subcutaneously at a fixed dose of 120 Anti-Xa IU/kg twice a day for 10 days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfractionated heparin administered intravenously.
Number of subjects: 60
Study: 1965113

Group type: EXPERIMENTAL
Intervention: Intranasal NPC 567 (bradykinin antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6162471

Group type: EXPERIMENTAL
Intervention: L-Tryptophan (50 mg/kg) administered twice daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-Tryptophan (50 mg/kg) administered either acutely or chronically
Number of subjects: 0
Study: 6321356

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1-2 g b.i.d.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 g b.i.d.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g u.i.d.)
Number of subjects: 60
Study: 31570105

Group type: EXPERIMENTAL
Intervention: Circulating free DNA (cfDNA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS) on circulating tumor DNA (ctDNA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Circulating free DNA (cfDNA) and circulating tumor DNA (ctDNA)
Number of subjects: 13
Study: 29337584

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 498
Study: 26708332

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 82
Study: 24643203

Group type: EXPERIMENTAL
Intervention: Rotigotine 8 mg/24 h
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514

Group type: COMPARATOR
Intervention: Rotigotine 8 mg/24 h vs Placebo
Number of subjects: 514
Study: 22503581

Group type: EXPERIMENTAL
Intervention: CHADS(2) score of 3 to 6
Number of subjects: 541

Group type: COMPARATOR
Intervention: CHADS(2) score of 0
Number of subjects: 541
Study: 20811078

Group type: EXPERIMENTAL
Intervention: Plyometric training (6 weeks, 3 times weekly)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 48
Study: 17635939

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (low‐fat dietary modification, weight loss, and physical activity intervention)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) users in intervention group
Number of subjects: 373
Study: 15716846

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 51

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 51
Study: 12087018

Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: IA-2 antibody positive, GAD antibody negative group
Number of subjects: 0
Study: 10443605

Group type: EXPERIMENTAL
Intervention: Mean skin temperature of 29 degrees C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mean skin temperature of 31.5 degrees C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mean skin temperature of 34 degrees C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 8
Study: 8777188

Group type: EXPERIMENTAL
Intervention: Negative feedback from a woman
Number of subjects: 137

Group type: COMPARATOR
Intervention: Neutral feedback from a woman
Number of subjects: 137

Group type: COMPARATOR
Intervention: Positive feedback from a woman
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High anger and hypermasculinity measures
Number of subjects: 137
Study: 2140735

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion at a rate of 0.06 ml/kg/min for 2 h in the supine position
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion at a rate of 0.06 ml/kg/min for 2 h in the seated position
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion in both positions
Number of subjects: 6
Study: 547544

Group type: EXPERIMENTAL
Intervention: 180 mg 17 beta‐estradiol or 250 mg estriol
Number of subjects: 105

Group type: COMPARATOR
Intervention: gel only (control group)
Number of subjects: 105
Study: 30007939

Group type: EXPERIMENTAL
Intervention: Exclusively breast milk (BM) group (proportion of BM=100%, n=56)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Predominantly formula-fed infants (BM ≤50%, n=38)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Predominantly BM group (BM 51%-99%, n=39)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Predominantly formula-fed group
Number of subjects: 133
Study: 29891406

Group type: EXPERIMENTAL
Intervention: School-based intervention to reduce sitting time, including classroom and outdoor environmental measures.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: School-based intervention to reduce sitting time.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 88
Study: 26874388

Group type: EXPERIMENTAL
Intervention: PA pressure-guided HF management plus standard of care
Number of subjects: 550

Group type: COMPARATOR
Intervention: Standard clinical assessment (blind therapy group)
Number of subjects: 550
Study: 23990195

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 328

Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 328

Group type: COMPARATOR
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 328
Study: 22773769

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (ERT) using Evorel patches
Number of subjects: 11

Group type: COMPARATOR
Intervention: No patch (control period)
Number of subjects: 11
Study: 20367730

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17470697

Group type: EXPERIMENTAL
Intervention: Vulnerability safety margin screening at 14 J
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Defibrillation safety margin screening at 14 J
Number of subjects: 426

Group type: COMPARATOR
Intervention: First shock efficacy
Number of subjects: 426
Study: 15093987

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg od
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 11399783

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg) three times daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chitosan (890 mg) three times daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of Orlistat vs Chitosan
Number of subjects: 12
Study: 9257889

Group type: EXPERIMENTAL
Intervention: HD‐CY (4 g/m2 i.v.) plus GM‐CSF (8 microg/kg/day s.c.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: G‐CSF (10 microg/kg/day s.c.) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HD‐CY plus GM‐CSF
Number of subjects: 40

Group type: COMPARATOR
Intervention: G‐CSF alone
Number of subjects: 40
Study: 7901864

Group type: EXPERIMENTAL
Intervention: Apomorphine 5 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apomorphine 10 micrograms/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3651279

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 72
Study: 31420414

Group type: EXPERIMENTAL
Intervention: Pertuzumab (840→420 mg every 3 weeks)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 156
Study: 28804870

Group type: EXPERIMENTAL
Intervention: TRIM
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 128
Study: 25795927

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (CBT) for perfectionism
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 42
Study: 23820187

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 44092

Group type: COMPARATOR
Intervention: Metoprolol or Atenolol
Number of subjects: 44092
Study: 21875697

Group type: EXPERIMENTAL
Intervention: Subinguinal varicocelectomy after 2 ml intratunical space injection of methylene blue
Number of subjects: 80

Group type: COMPARATOR
Intervention: No mapping technique during subinguinal varicocelectomy
Number of subjects: 80
Study: 19701034

Group type: EXPERIMENTAL
Intervention: Periodontal treatment (scaling and root planing early in the second trimester)
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Delayed treatment (periodontal care after delivery)
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 1760
Study: 17043961

Group type: EXPERIMENTAL
Intervention: Supportan (enteral nutrition specific for tumor patients)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Basic diet (control group)
Number of subjects: 66
Study: 15209485

Group type: EXPERIMENTAL
Intervention: Intrauterine myelomeningocele repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 11422091

Group type: EXPERIMENTAL
Intervention: 200 mg qd lanepitant
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 8637697

Group type: EXPERIMENTAL
Intervention: Local anesthetic injection at 37 degrees C (body temperature)
Number of subjects: 40
Study: 1569226

Group type: EXPERIMENTAL
Intervention: Potassium citrate‐SMFP dentifrice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Potassium nitrate‐SMFP dentifrice
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control SMFP dentifrice (no potassium salt)
Number of subjects: 120
Study: 6378437

Group type: COMPARATOR
Intervention: Indomethacin, 25 mg tds
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aspirin-SR, 650 mg daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Paracetamol, 1 g 8th hourly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Naproxen, 250 mg mane and 500 mg nocte
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sulindac, 200 mg bd
Number of subjects: 70
Study: 30831333

Group type: EXPERIMENTAL
Intervention: AMPLATZER Amulet device
Number of subjects: 1878

Group type: COMPARATOR
Intervention: Boston Scientific WATCHMAN device
Number of subjects: 1878
Study: 29522535

Group type: EXPERIMENTAL
Intervention: Middle levels of perceived stress
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: High levels of perceived stress
Number of subjects: 523

Group type: COMPARATOR
Intervention: Lowest levels of perceived stress
Number of subjects: 523
Study: 26070532

Group type: EXPERIMENTAL
Intervention: Sinemet CR (bedtime)
Number of subjects: 57
Study: 24722423

Group type: EXPERIMENTAL
Intervention: Jinzhen oral liquid
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 23379201

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% (instilled twice-daily)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% (instilled 4-times daily)
Number of subjects: 267
Study: 20199178

Group type: COMPARATOR
Intervention: Captopril 25 mg three times a day (Group 1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg and pentoxifylline 400 mg each three times per day (Group 2)
Number of subjects: 74
Study: 18572088

Group type: EXPERIMENTAL
Intervention: Dietary protocol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nondiet group
Number of subjects: 49
Study: 16079371

Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 11849194

Group type: EXPERIMENTAL
Intervention: Liquid formulation of 1 g paracetamol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tablets of paracetamol
Number of subjects: 12
Study: 10029055

Group type: EXPERIMENTAL
Intervention: Ultralight wheelchair
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard wheelchair
Number of subjects: 74
Study: 7737532

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Spectrotypic analysis of antibody response
Number of subjects: 67
Study: 1413291

Group type: EXPERIMENTAL
Intervention: Preventive protocol for hypertension screening
Number of subjects: 1700
Study: 4064468

Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide and 80% oxygen
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 12
Study: 30950565

Group type: COMPARATOR
Intervention: GSK3008356 single doses (5 to 200 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: GSK3008356 repeat doses (1, 3, and 10 mg twice daily for 14 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: GSK3008356 single doses
Number of subjects: 104

Group type: COMPARATOR
Intervention: GSK3008356 repeat doses
Number of subjects: 104

Group type: COMPARATOR
Intervention: GSK3008356
Number of subjects: 104

Group type: COMPARATOR
Intervention: GSK3008356 higher doses
Number of subjects: 104
Study: 29959048

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 37
Study: 27092862

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) plus treatment as usual (TAU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 29
Study: 23510665

Group type: EXPERIMENTAL
Intervention: PVRV-NG
Number of subjects: 384

Group type: COMPARATOR
Intervention: Verorab
Number of subjects: 384
Study: 21327534

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 40
Study: 19735515

Group type: EXPERIMENTAL
Intervention: Hydrating gel-cream (active product)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Gel-cream without active substances (placebo)
Number of subjects: 66
Study: 17317205

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6mg single dose on day 2 of FEC-100) - Primary Prophylaxis (PP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6mg single dose on day 2 of FEC-100) - Secondary Prophylaxis (SP)
Number of subjects: 60
Study: 15541132

Group type: EXPERIMENTAL
Intervention: 1% silver nitrate
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 0.2% povidone iodine
Number of subjects: 106

Group type: COMPARATOR
Intervention: 50% dextrose
Number of subjects: 106
Study: 11303547

Group type: EXPERIMENTAL
Intervention: Acupressure wristband
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 9815633

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (PPS) administered orally (p.o.) at doses of 180, 270, and 400 mg/m2 t.i.d.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (PPS) administered orally (p.o.) at doses of 400 mg/m2 t.i.d.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (PPS) administered orally (p.o.) at various doses.
Number of subjects: 21
Study: 8230266

Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg/d orally for 2 years
Number of subjects: 17
Study: 2869951

Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 20 mg bisoprolol
Number of subjects: 48
Study: 29939421

Group type: EXPERIMENTAL
Intervention: Euglycaemic clamp (5-6 mmol/l)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp (9-10 mmol/l)
Number of subjects: 8
Study: 26214555

Group type: EXPERIMENTAL
Intervention: Fluvastatin (10 mg daily)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Valsartan (20 mg daily)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fluvastatin and Valsartan combination (10 mg and 20 mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 130
Study: 24997178

Group type: EXPERIMENTAL
Intervention: MGDRx EyeBag (heated device)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-heated device (control)
Number of subjects: 25
Study: 22230203

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hospital follow-up
Number of subjects: 65
Study: 20046171

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ultrasonic therapy (UST)
Number of subjects: 45
Study: 17912501

Group type: EXPERIMENTAL
Intervention: Sulpiride 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulpiride 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15868614

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 636

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study: 12421850

Group type: EXPERIMENTAL
Intervention: [6S]-5-methyltetrahydrofolate (113 micro g/d)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Folic acid (100 micro g/d)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104